Experimental: DaRT seeds

DEVICE2 trials

Sponsors

Alpha Tau Medical LTD.

Conditions

Locally Recurrent Prostate CancerMalignant TumorNon-metastatic Prostate Cancer

Unknown Phase

Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors

RecruitingNCT05781555

Alpha Tau Medical LTD.Malignant Tumor

Start: 2023-03-22End: 2027-04-01Target: 100Updated: 2026-06-16

Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

RecruitingNCT06202248

Alpha Tau Medical LTD.Locally Recurrent Prostate Cancer, Non-metastatic Prostate Cancer

Start: 2024-03-12End: 2027-06-01Target: 10Updated: 2026-06-16

Related Papers

Combined safety and efficacy results from three clinical studies evaluating alpha radiotherapy for advanced pancreatic cancer.

Journal of Clinical Oncology2026-05-27

Interim analysis of feasibility, safety, and tumor control in two first-in-human trials of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma.

Journal of Clinical Oncology2025-01-27